Physician profile
Sudarshan Chatterjee
NPI 1750465712
$4,128.34
in general payments reported to CMS, 2019-2025
29 companies · $595 in 2025
The $595 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2022: $517 · 2023: $1,422 · 2024: $1,308 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,177 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.64 |
| Education | $148.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $547.16 | 2022-2025 | Repatha, Tezspire |
| Novartis Pharmaceuticals Corporation | $328.85 | 2023-2025 | |
| Pfizer INC. | $317.71 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $288.26 | 2022-2025 | Camzyos, Eliquis |
| Harmony Biosciences LLC | $286.43 | 2023-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.27 | 2022-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $218.49 | 2022-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $206.97 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $205.95 | 2019-2025 | Airsupra, Wainua |
| Merck Sharp & Dohme LLC | $196.08 | 2022-2024 | Verquvo |
| Novo Nordisk INC | $190.88 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $172.60 | 2019-2024 | Varithena Administration Pack |
| Kiniksa Pharmaceuticals, LTD. | $167.59 | 2022-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $166.25 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.01 | 2022-2025 | Lifevest |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $70.81 | 2023 | Ffrct |
| Scpharmaceuticals INC. | $66.93 | 2023-2025 | |
| United Therapeutics Corporation | $47.03 | 2024 | Tyvaso |
| Avadel Cns Pharmaceuticals, LLC | $28.54 | 2024 | Lumryz |
| Lantheus Medical Imaging, INC. | $28.11 | 2023 | Definity |
| Esperion Therapeutics, INC. | $27.79 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $25.79 | 2023 | |
| Impulse Dynamics (USA) INC. | $24.20 | 2023 | Optimizer |
| Inspire Medical Systems, INC. | $23.07 | 2023 | Inspire |
| Medtronic Vascular, INC. | $23.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.89 | 2024 | |
| Glaxosmithkline, LLC. | $17.16 | 2024 | Nucala |
| W. L. Gore & Associates, INC. | $14.28 | 2019 | |
| Altathera Pharmaceuticals LLC | $6.22 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudarshan Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.